Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Am J Transplant. 2023 Aug;23(8):1256-1263. doi: 10.1016/j.ajt.2023.04.028. Epub 2023 May 6.
Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature, with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and posttransplant outcomes, including CAV. We analyzed 479 HT recipients with stored DNA samples at 2 high-volume transplant centers, Vanderbilt University Medical Center and Columbia University Irving Medical Center. We explored the association between the presence of CHIP mutations with CAV and mortality after HT. In this case-control analysis, carriers of CHIP mutations were not at increased risk of CAV or mortality after HT. In a large multicenter genomics study of the heart transplant population, the presence of CHIP mutations was not associated with an increased risk of CAV or posttransplant mortality.
心脏移植后心脏同种异体移植物血管病(CAV)是晚期移植物失功和死亡的主要原因。CAV 具有动脉粥样硬化的一些特征,导致心外膜冠状动脉和微血管弥漫性狭窄,进而导致移植物缺血。最近,不定潜能的克隆性造血(CHIP)已成为心血管疾病和死亡率的一个危险因素。我们旨在研究 CHIP 与移植后结局(包括 CAV)之间的关系。我们分析了范德比尔特大学医学中心和哥伦比亚大学欧文医学中心 2 个大容量移植中心的 479 例有储存 DNA 样本的 HT 受者。我们探讨了 CHIP 突变的存在与 HT 后 CAV 和死亡率之间的关联。在这项病例对照分析中,携带 CHIP 突变的患者发生 CAV 或 HT 后死亡的风险没有增加。在一项针对心脏移植人群的大型多中心基因组学研究中,CHIP 突变的存在与 CAV 或移植后死亡率增加无关。